H.C. Wainwright has downgraded Syros Pharmaceuticals (NASDAQ:SYRS) to neutral from buy, citing Tuesday’s announcement that a ...

Fintel reports that on November 13, 2024, TD Cowen downgraded their outlook for Syros Pharmaceuticals (NasdaqGS:SYRS) from ...

H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after ...

The interiors similarly would be different and would be similar to the EV9 with a clean minimalistic look while it would be ...

Find out the latest Kia Syros car price, reviews, specifications, images, mileage, videos and more. Get expert reviews on the ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

The latter court retried the case and ultimately upheld the same sentences as the Five-Member Court of Appeals in Syros.

Brookline downgraded Syros Pharmaceuticals (SYRS) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot ...

NEW YORK – Syros Pharmaceuticals said on Tuesday that its retinoic acid receptor-alpha agonist tamibarotene, which it was testing in combination with azacitidine in patients newly diagnosed with ...

Strofilas, on the island of Andros in Greece, is the oldest city in Europe. Dating back to 4500 — 3200 BC, is the largest ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.13%, Germany's DAX fell 0.16% and France's CAC 40 ...